Product Pipeline

Zumutor is a leading Immuno-Oncology company focused on developing targeted NK cell therapeutics

TARGET	DISEASE INDICATIONS	STATUS – KEY DATA	MILESTONE
ZM008 Lead Asset Anti-LLT1 mAb (Potential first-in-class antibody targeting LLT1-Lectin Like Transcript 1)	Prostate Cancer, B cell lymphoma, Glioblastoma, Rheumatoid Arthritis	Strong in-vitro and in-vivo preclinical data demonstrates tumor cell death, immune cell infiltration and tumor growth inhibition Completed transfer to Catalent-produced Tox material Patient tissue data analysis at Mount Sinai and HCG in progress	Development on track for Investigational New Drug (IND) filing in mid CY2021 Phase I clinical trials readiness likely by Q3 2021
ZM012 mAb target. Functions through tumour associated antigen/NK cell receptor	Lymphoma and other Undisclosed indications	Unique Clone identification in process	Animal Efficacy – Q2 2021
ZM014 mAb target. Functions through tumour NK cell receptor	Lymphoma	Unique Clone identification in process	Animal Efficacy – Q 4 2020

TARGET

DISEASE INDICATIONS

STATUS – KEY DATA

MILESTONE

ZM008

Lead Asset
Anti-LLT1 mAb
(Potential first-in-class antibody targeting LLT1-Lectin Like Transcript 1)

Prostate Cancer,
B cell lymphoma, Glioblastoma, Rheumatoid Arthritis

Strong in-vitro and in-vivo preclinical data demonstrates tumor cell death, immune cell infiltration and tumor growth inhibition
Completed transfer to Catalent-produced Tox material
Patient tissue data analysis at Mount Sinai and HCG in progress

ZM012

mAb target. Functions through tumour associated antigen/NK cell receptor

Lymphoma and other Undisclosed indications

Animal Efficacy –
Q2 2021

ZM014

mAb target. Functions through tumour NK cell receptor

Lymphoma

Animal Efficacy –
Q 4 2020

Molecules for NK cell and cell targets under development

Future targets of interest

In vivo efficacy study completed

Selection of Ab producing stable cell lines.
Process development large scale manufacture

Stability studies,

CMC Package Development